Low molecular-weight heparin for thromboprophylaxis in patients undergoing gastric cancer surgery: an experience from one Korean institute.
10.4174/astr.2014.86.1.22
- Author:
Sung Ho CHOI
1
;
Jung Ho SHIM
;
Cho Hyun PARK
;
Kyo Young SONG
Author Information
1. Division of Gastrointestinal Surgery, Department of Surgery, The Catholic University of Korea School of Medicine, Seoul, Korea. skygs@catholic.ac.kr
- Publication Type:Clinical Trial ; Original Article
- Keywords:
Feasibility;
Low-molecular-weight heparin;
Thromboembolism;
Stomach cancer;
Korea
- MeSH:
Body Mass Index;
Enoxaparin;
Hemorrhage;
Heparin*;
Heparin, Low-Molecular-Weight;
Humans;
Korea;
Medical Records;
Prospective Studies;
Sodium;
Stomach Neoplasms*;
Thromboembolism;
Venous Thromboembolism
- From:Annals of Surgical Treatment and Research
2014;86(1):22-27
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study evaluated the efficacy for preventing venous thromboembolism (VTE) and adverse effects of low-molecular-weight heparin (LMWH) in order to launch a prospective clinical trial in Korea. METHODS: We reviewed the medical records of 108 consecutive patients who underwent gastric cancer surgery. These patients were divided into 2 groups according to the type of thromboprophylaxis: group A, LMWH combined with intermittent pneumatic compression (IPC); group B, IPC alone. The postoperative outcomes of the two groups were compared. RESULTS: Symptomatic VTE was observed in only 1 patient (0.9%) from group B. Postoperative bleeding was more common in group A than in group B (10.9% vs. 7.5%), although the difference was not significant (P = 0.055). Most bleeding episodes were minor and managed conservatively without intervention. Only a high body mass index was associated with a significantly increased risk of postoperative bleeding (odds ratio, 1.45; 95% confidence interval, 1.12-2.43; P = 0.051). CONCLUSION: A 40 mg of enoxaparin sodium is a safe and feasible dose for prevention of VTE. With the results of this study, we are planning a prospective randomized clinical trial to investigate the clinical efficacy of LMWH thromboprophylaxis in gastric cancer patients in Korea.
